IL219051A - Methods for predicting clinical outcome of cancer - Google Patents

Methods for predicting clinical outcome of cancer

Info

Publication number
IL219051A
IL219051A IL219051A IL21905112A IL219051A IL 219051 A IL219051 A IL 219051A IL 219051 A IL219051 A IL 219051A IL 21905112 A IL21905112 A IL 21905112A IL 219051 A IL219051 A IL 219051A
Authority
IL
Israel
Prior art keywords
cancer
methods
clinical outcome
predict clinical
predict
Prior art date
Application number
IL219051A
Other languages
English (en)
Hebrew (he)
Other versions
IL219051A0 (en
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of IL219051A0 publication Critical patent/IL219051A0/en
Publication of IL219051A publication Critical patent/IL219051A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL219051A 2009-11-23 2012-04-04 Methods for predicting clinical outcome of cancer IL219051A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26376309P 2009-11-23 2009-11-23
PCT/US2010/057490 WO2011063274A2 (en) 2009-11-23 2010-11-19 Methods to predict clinical outcome of cancer

Publications (2)

Publication Number Publication Date
IL219051A0 IL219051A0 (en) 2012-06-28
IL219051A true IL219051A (en) 2016-12-29

Family

ID=44060376

Family Applications (5)

Application Number Title Priority Date Filing Date
IL219051A IL219051A (en) 2009-11-23 2012-04-04 Methods for predicting clinical outcome of cancer
IL249159A IL249159A0 (en) 2009-11-23 2016-11-23 Methods for predicting clinical outcome of cancer
IL257063A IL257063B (en) 2009-11-23 2018-01-21 Methods for predicting clinical outcome of cancer
IL264072A IL264072B (en) 2009-11-23 2019-01-03 Methods for predicting clinical outcome of cancer
IL276487A IL276487B (en) 2009-11-23 2020-08-04 Methods for predicting clinical outcome of cancer

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL249159A IL249159A0 (en) 2009-11-23 2016-11-23 Methods for predicting clinical outcome of cancer
IL257063A IL257063B (en) 2009-11-23 2018-01-21 Methods for predicting clinical outcome of cancer
IL264072A IL264072B (en) 2009-11-23 2019-01-03 Methods for predicting clinical outcome of cancer
IL276487A IL276487B (en) 2009-11-23 2020-08-04 Methods for predicting clinical outcome of cancer

Country Status (13)

Country Link
US (4) US20110123990A1 (enExample)
EP (4) EP3556867A1 (enExample)
JP (7) JP5964752B2 (enExample)
AU (1) AU2010321829B2 (enExample)
CA (2) CA3043089A1 (enExample)
DK (1) DK2504451T3 (enExample)
ES (1) ES2735993T3 (enExample)
HU (1) HUE044374T2 (enExample)
IL (5) IL219051A (enExample)
MX (3) MX363817B (enExample)
NZ (1) NZ599194A (enExample)
PL (1) PL2504451T3 (enExample)
WO (1) WO2011063274A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
MX2010014280A (es) * 2008-06-26 2011-05-23 Dana Farber Cancer Inst Inc Distintivos y determinantes asociados con metástasis y método para utilizarlos.
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
JP5964752B2 (ja) * 2009-11-23 2016-08-03 ジェノミック ヘルス， インコーポレイテッド 癌の臨床転帰を予測する方法
MX375138B (es) 2010-01-11 2025-03-06 Genomic Health Inc Método para usar expresión génica para determinar la probabilidad de un desenlace clínico de cáncer renal.
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
US20120053253A1 (en) 2010-07-07 2012-03-01 Myriad Genetics, Incorporated Gene signatures for cancer prognosis
EP2913405B1 (en) 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
EP2611941A4 (en) 2010-08-30 2014-01-22 Myriad Genetics Inc GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
CA2831074A1 (en) * 2011-03-26 2012-10-04 Oregon Health And Science University Gene expression predictors of cancer prognosis
CA2840472A1 (en) * 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
WO2013006495A2 (en) * 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
AU2012281152B2 (en) * 2011-07-13 2017-09-07 The Multiple Myeloma Research Foundation, Inc. Methods for data collection and distribution
EP2744917A4 (en) * 2011-08-16 2015-10-14 Oncocyte Corp METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER
WO2013070521A1 (en) * 2011-11-08 2013-05-16 Genomic Health, Inc. Method of predicting breast cancer prognosis
JP5805518B2 (ja) * 2011-12-21 2015-11-04 株式会社島津製作所 マルチプレックス大腸がんマーカーパネル
US8725426B2 (en) 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
GB201206323D0 (en) * 2012-04-10 2012-05-23 Immunovia Ab Methods and arrays for use in the same
EP2839034A4 (en) * 2012-04-20 2016-01-06 Sloan Kettering Inst Cancer ASSOCIATED GENE EXPRESSION PROFILES ASSOCIATED WITH METASTASISING BREAST CANCER
WO2014055398A1 (en) 2012-10-05 2014-04-10 Siemens Healthcare Diagnostics Inc. Method for detecting an increased risk or incidence of colorectal cancer
ES2938766T3 (es) 2012-11-16 2023-04-14 Myriad Genetics Inc Firmas génicas para el pronóstico de cáncer
KR101672531B1 (ko) * 2013-04-18 2016-11-17 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도
US10181008B2 (en) * 2013-05-30 2019-01-15 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
WO2014195032A1 (en) * 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2015138769A1 (en) * 2014-03-12 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for assessing patients with non-small cell lung cancer
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
WO2016092299A1 (en) * 2014-12-09 2016-06-16 Medical Research Council Methods and kits for predicting the response to therapy of cancer
EP3274440B1 (en) 2015-03-27 2026-03-04 Exact Sciences Corporation Detecting esophageal disorders
KR102811214B1 (ko) 2015-10-30 2025-05-27 이그잭트 사이언시즈 코포레이션 복합 증폭 검출 분석 및 혈장으로부터 dna의 분리 및 검출 방법
EP3389481A4 (en) 2015-12-18 2019-05-22 Clear Gene, Inc. PROCESSES, COMPOSITIONS, KITS AND DEVICES FOR FAST LANALYSIS OF BIOLOGICAL MARKERS
SG11201901466PA (en) * 2016-09-07 2019-03-28 Agency Science Tech & Res A method of identifying risk of cancer and therapeutic options
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
JP7289264B2 (ja) 2017-01-27 2023-06-09 エグザクト サイエンシーズ コーポレーション メチル化ｄｎａの分析による結腸腫瘍の検出
WO2018212192A1 (ja) * 2017-05-18 2018-11-22 京都府公立大学法人 癌の予後及び／又は転移可能性を評価する方法及びマーカー
US12275994B2 (en) * 2017-06-22 2025-04-15 Clear Gene, Inc. Methods and compositions for the analysis of cancer biomarkers
CA3036161C (en) 2017-11-13 2023-03-28 The Multiple Myeloma Research Foundation, Inc. Integrated, molecular, omics, immunotherapy, metabolic, epigenetic, and clinical database
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
US11549152B2 (en) * 2018-03-08 2023-01-10 University Of Notre Dame Du Lac Products for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon
JP7199045B2 (ja) * 2018-04-13 2023-01-05 国立大学法人大阪大学 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム
US20220120753A1 (en) * 2018-09-21 2022-04-21 The University Of Tokyo Method for determining prognosis of cancer
JP2019032334A (ja) * 2018-10-03 2019-02-28 イムノヴィア・アクチエボラーグ 乳癌関連の疾患状態を決定する方法およびこの方法における使用のためのアレイ
KR102216645B1 (ko) * 2018-10-29 2021-02-17 사회복지법인 삼성생명공익재단 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도
MX2021006560A (es) * 2018-12-08 2021-11-17 Pfs Genomics Inc Perfilado transcriptómico para prognosis de cáncer de mama.
SG11202111940XA (en) * 2019-05-03 2021-12-30 Dcgen Co Ltd Method of predicting cancer prognosis and composition for same
CN111235270B (zh) * 2019-08-29 2022-04-29 北京臻知医学科技有限责任公司 一种基于高通量测序法的肿瘤抗原表达检测引物及试剂盒
US12165747B2 (en) * 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
AU2022220330A1 (en) * 2021-02-12 2023-09-14 Mammogen, Inc. Biomarkers for the diagnosis of breast cancer
WO2022192128A2 (en) * 2021-03-08 2022-09-15 Castle Biosciences, Inc. Determining prognosis and treatment based on clinical-pathologic factors and continuous multigene-expression profile scores
CN117116345B (zh) * 2023-07-24 2025-09-16 中国人民解放军军事科学院军事医学研究院 一种基于基因调控网络构建患者生存网络的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1410011T3 (da) 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnose og prognose for brystcancerpatienter
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
DK3115470T3 (en) * 2002-03-13 2018-11-05 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
US20040067234A1 (en) * 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
ES2905579T3 (es) * 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
WO2005086891A2 (en) * 2004-03-05 2005-09-22 Rosetta Inpharmatics Llc Classification of breast cancer patients using a combination of clinical criteria and informative genesets
CA2582739A1 (en) * 2004-09-30 2006-04-13 Bayer Healthcare Ag Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
JP2008534002A (ja) 2005-04-01 2008-08-28 エヌシィーシィー テクノロジー ベンチャーズ ピィーティーイー．リミテッド 乳癌の分類に関する材料および方法
WO2006133460A2 (en) 2005-06-09 2006-12-14 Yale University Methods for diagnosing and treating breast cancer based on a her/er ratio
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
TWI304443B (en) * 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
US7888019B2 (en) * 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
US20100234292A1 (en) * 2007-04-16 2010-09-16 Ipsogen Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
WO2009095319A1 (en) * 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
WO2009132928A2 (en) * 2008-05-02 2009-11-05 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis
CA2723972A1 (en) * 2008-05-12 2009-11-19 Genomic Health Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
JP5964752B2 (ja) * 2009-11-23 2016-08-03 ジェノミック ヘルス， インコーポレイテッド 癌の臨床転帰を予測する方法

Also Published As

Publication number Publication date
JP2022169647A (ja) 2022-11-09
JP2021058207A (ja) 2021-04-15
PL2504451T3 (pl) 2019-09-30
CA3043089A1 (en) 2011-05-26
JP2022166064A (ja) 2022-11-01
JP7823012B2 (ja) 2026-03-03
JP2016214245A (ja) 2016-12-22
US20190241967A1 (en) 2019-08-08
EP2504451B1 (en) 2019-06-05
IL264072B (en) 2020-08-31
MX337650B (es) 2016-03-14
EP3556867A1 (en) 2019-10-23
EP3739060A1 (en) 2020-11-18
US20170211154A1 (en) 2017-07-27
IL276487A (en) 2020-09-30
EP2504451A2 (en) 2012-10-03
MX391499B (es) 2025-03-21
US20110123990A1 (en) 2011-05-26
WO2011063274A3 (en) 2014-03-27
CA2776751A1 (en) 2011-05-26
MX363817B (es) 2019-04-04
CA2776751C (en) 2019-07-02
DK2504451T3 (da) 2019-08-05
MX2019003811A (es) 2019-08-05
MX2012005822A (es) 2012-06-19
HUE044374T2 (hu) 2019-10-28
IL257063B (en) 2019-01-31
IL276487B (en) 2022-03-01
JP5964752B2 (ja) 2016-08-03
ES2735993T3 (es) 2019-12-23
JP2013514058A (ja) 2013-04-25
JP7042717B2 (ja) 2022-03-28
IL219051A0 (en) 2012-06-28
AU2010321829A1 (en) 2012-05-03
JP2018196385A (ja) 2018-12-13
EP4350001A3 (en) 2024-06-19
NZ599194A (en) 2014-07-25
US20210062275A1 (en) 2021-03-04
IL249159A0 (en) 2017-01-31
EP4350001A2 (en) 2024-04-10
JP2024037948A (ja) 2024-03-19
WO2011063274A2 (en) 2011-05-26
AU2010321829B2 (en) 2015-07-30
IL264072A (en) 2019-02-28
EP2504451A4 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
IL276487B (en) Methods for predicting clinical outcome of cancer
IL276362A (en) Cancer treatment methods
IL251635A0 (en) A method for using gene expression to determine the likelihood of clinical outcome in kidney cancer
IL218575A0 (en) Treatment of cancer
ZA201206019B (en) Methods for predicting response of triple-negative breast cancer to therapy
SI2297359T1 (sl) Profili genskega izraĹľanja za napovedovanje izida raka dojke
EP2438197A4 (en) METHOD OF CANCER DETECTION
ZA201208821B (en) Methods of treatment of pancreatic cancer
EP2575803A4 (en) METHOD OF TREATING BLADDER CANCER
PT2435825E (pt) Métodos para o tratamento de doenças
EP2461814A4 (en) PROSTATE CANCER TREATMENT
SG10201508495VA (en) Combination treatment of cancer
ZA201304225B (en) Methods of treating cancer
EP2640390A4 (en) METHODS OF TREATING CANCER
IL218230A0 (en) Method of treating cancer
EP2593100A4 (en) METHOD OF TREATING REFRACTORY CANCER
IL213919A0 (en) Methods to treat cancer
IL216580A0 (en) Use of anti-sparc antibodies to predict response to chemothrapy
GB0916686D0 (en) Treatment of cancer
GB0921757D0 (en) Treatment of cancer
IL223237A0 (en) Diagnosis of cancer
GB201017354D0 (en) Treatment of cancer
GB201007977D0 (en) Treatment of cardiovascular disease
GB0906490D0 (en) Use of tetanolic for treatment of breast cancer
GB0908666D0 (en) Treatment of proteostatic disease

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed